Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Compass Therapeutics, Inc. (CMPX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Compass Therapeutics, Inc. (CMPX) Discusses Positive Secondary Endpoint Results From COMPANION-002 Study in Advanced Biliary Tract Cancer Transcript
Compass Therapeutics, Inc. (CMPX) Discusses Positive Secondary Endpoint Results From COMPANION-002 Study in Advanced Biliary Tract Cancer Transcript
Is Compass Therapeutics, Inc. (CMPX) Outperforming Other Medical Stocks This Year?
Here is how Compass Therapeutics, Inc. (CMPX) and Ekso Bionics (EKSO) have performed compared to their sector so far this year.
Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 113.7% in Compass Therapeutics, Inc. (CMPX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year?
Here is how Compass Therapeutics, Inc. (CMPX) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
Wall Street Analysts Think Compass Therapeutics, Inc. (CMPX) Could Surge 134.14%: Read This Before Placing a Bet
The consensus price target hints at a 134.1% upside potential for Compass Therapeutics, Inc. (CMPX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why Compass Therapeutics, Inc. (CMPX) is a Great Momentum Stock to Buy
Does Compass Therapeutics, Inc. (CMPX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Compass Therapeutics, Inc. (CMPX) Presents at Evercore 8th Annual Healthcare Conference Transcript
Compass Therapeutics, Inc. (CMPX) Presents at Evercore 8th Annual Healthcare Conference Transcript
Compass Therapeutics, Inc. (CMPX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Compass Therapeutics, Inc. (CMPX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Wall Street Analysts Believe Compass Therapeutics, Inc. (CMPX) Could Rally 154.09%: Here's is How to Trade
The mean of analysts' price targets for Compass Therapeutics, Inc. (CMPX) points to a 154.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2025's Top 3 Breakout Stocks for Active Traders: Don't Miss Out!
ORLA, FIGS and CMPX emerge as breakout candidates as traders scan for stocks nearing or clearing key resistance levels.
Compass Therapeutics, Inc. (CMPX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
Compass Therapeutics, Inc. (NASDAQ:CMPX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 5:35 PM EDT Company Participants Thomas Schuetz - CEO & Vice Chairman Barry Shin - Chief Financial Officer Conference Call Participants Kelly McCarthy Presentation Kelly McCarthy Good afternoon, everyone. This is Kelly McCarthy from the Morgan Stanley Healthcare team, and it's great to be here with the management team of Compass Therapeutics.
